Issue 6/2006
Content (17 Articles)
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR
Diane Balin-Gauthier, Jean-Pierre Delord, Philippe Rochaix, Valérie Mallard, Fabienne Thomas, Isabelle Hennebelle, Roland Bugat, Pierre Canal, Cuider Allal
4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers
David Eilender, Patricia LoRusso, Leonard Thomas, Catherine McCormick, Andrew H. Rodgers, Catherine L. Hooper, Karl Tornyos, Edward T. Krementz, Steven Parker, Lee Roy Morgan
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours
Iñaki F. Trocòniz, María J. Garrido, Cristina Segura, Josep-María Cendrós, Paola Principe, Concepción Peraire, Rosendo Obach
A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer
Shuichi Hokita, Takashi Aikou, Futoshi Miyazono, Sumiya Ishigami, Kuniaki Aridome, Shigeho Maenohara, Tetsushi Saihara, Kuniaki Suenaga, Hidehiro Nomura, Satoshi Maeda, Hiroyuki Takatori, Hideo Arima, Yasuto Uchikado, Shoji Natsugoe, Sonshin Takao
Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells
Diane F. Matesic, Kimberly N. Villio, Stacey L. Folse, Erin L. Garcia, Stephen J. Cutler, Horace G. Cutler
A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer
Keiichi Fujiwara, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Katsuyuki Hotta, Shigeki Umemura, Keisuke Sugimoto, Takuo Shibayama, Haruhito Kamei, Shingo Harita, Niro Okimoto, Mitsune Tanimoto
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
Lucy Lee, Sunil Sharma, Bruno Morgan, Peter Allegrini, Christian Schnell, Josef Brueggen, Robert Cozens, Mark Horsfield, Clemens Guenther, Will P. Steward, Joachim Drevs, David Lebwohl, Jeanette Wood, Paul M. J. McSheehy
Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine
Hitoshi Someya, William R. Waud, William B. Parker
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
Goli Samimi, Stephen B. Howell
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
Dale Schaar, Lauri Goodell, Joseph Aisner, Xiao Xing Cui, Zheng Tao Han, Richard Chang, John Martin, Stephanie Grospe, Liesel Dudek, Joan Riley, Jacqueline Manago, Yong Lin, Eric H. Rubin, Allan Conney, Roger K. Strair
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
G. P. Stathopoulos, Ch. Christodoulou, J. Stathopoulos, D. Skarlos, S. K. Rigatos, Th. Giannakakis, O. Armenaki, D. Antoniou, A. Athanasiadis, P. Giamboudakis, J. Dimitroulis, N. Georgatou, K. Katis
The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1α in mice
Barbara A. E. de Koning, Dicky J. Lindenbergh-Kortleve, Rob Pieters, Edmond H. H. M. Rings, Hans A. Büller, Ingrid B. Renes, Alexandra W. C. Einerhand
In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin)
Jung Su Ryu, Hong Sub Lee, Young-Soo Hong, Jung Joon Lee, Uy Dong Sohn, Tae Yong Kim
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice
Rogier R. Press, Tessa Buckle, Jos H. Beijnen, Olaf van Tellingen
Pharmacodynamic properties of methotrexate and AminotrexateTM during weekly therapy
Peter D. Cole, María José Alcaraz, Angela K. Smith, John Tan, Barton A. Kamen
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
E. Marcuello, A. Altés, A. Menoyo, E. Del Rio, M. Baiget